Efficacy and safety of combined therapy with terazosin and tolteradine for patients with lower urinary tract symptoms associated with benign prostatic hyperplasia: A prospective study

Chinese Medical Journal

Volumn 120, Issue 5, 2007, Pages 370-374

  Yang, Yong ^a   Zhao, Xiao Feng ^b   Li, Han Zhong ^b   Wang, Wei ^a   Zhang, Yong ^a   Xiao, He ^a   Zhang, Xin ^a  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

Author keywords

Combined therapy; Lower urinary tract symptoms; Prostatic hyperplasia

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; TERAZOSIN; TOLTERODINE;

ADULT; AGED; ARTICLE; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DIZZINESS; DRUG SAFETY; DRY EYE; DYSPEPSIA; GASTROINTESTINAL SYMPTOM; HUMAN; INTERNATIONAL PROSTATE SYMPTOM SCORE; INTRAOCULAR PRESSURE; KIDNEY DYSFUNCTION; LIVER DYSFUNCTION; LOWER URINARY TRACT SYMPTOM; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; ORGAN SIZE; PROSTATE; PROSTATE HYPERTROPHY; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; RESIDUAL URINE; SIDE EFFECT; URINARY FREQUENCY; URINARY URGENCY; URINE FLOW RATE; URINE INCONTINENCE; XEROSTOMIA;

EID: 33947674058     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.1097/00029330-200703010-00004     Document Type: Article

References (21)

1. Thomas AW, Cannon A, Bartlett E, Ellis-Jones J, Abrams P. The natural history of lower urinary tract dysfunction in men: minimum 10-year urodynamic follow-up of untreated bladder outlet obstruction. BJU Int 2005; 96: 1301-1306.
2. Eckhardt MD, van Venrooij GE, Boon TA. Symptoms and quality of life versus age, prostate volume, and urodynamics parameters in 565 strictly selected men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia. Urology 2001; 57: 695-700.
3. Mirone V, Imbimbo C, Longo N, Fusco F. The detrusor muscle: an innocent victim of bladder outlet obstruction. Eur Urol 2007; 51: 57-66.
4. Jolleys JV, Donovan JL, Nanchahal K, Peters TJ, Abrams P. Urinary symptoms in the community: how bothersome are they? Br J Urol 1994; 74: 551-555.
5. Bruskewitz RC. Quality of life and sexual function in patients with benign prostatic hyperplasia. Rev Urol 2003; 5: 72-80.
6. Schulman CC, Tamsulosin IN, Kirby R, McConnel JD, Fitzpatrick JM, Roehrborn CG, et al, eds. Textbook of benign prostatic hyperplasia. Oxford: Isis Medical Media Ltd; 1996: 307-323.
7. McConnell JD. Finateride therapy for benign prostatic hyperplasia. In: Kirby R, McConnell JD, Fitzpatrick JM, Roehrborn CG, Boyle P, eds. Textbook of benign prostatic hyperplasia. Oxford: Isis Medical Media Ltd; 1996: 259-265.
8. Irani J, Brown CT, van der Meulen J, Emberton M. A review of guidelines on benign prostatic hyperplasia and lower urinary tract symptoms: are all guidelines the same? BJU Int 2003; 92: 937-942.
9. Collins GN, Lee RJ, Russell EB, Raab GM, Hehir M. Ultrasonically determined patterns of enlargement in benign prostatic hyperplasia. Br J Urol 1993; 71: 451-456.
10. De Gennaro M, Capitanucci ML, Di Ciommo V, Adorisio O, Mosiello G, Orazi C, et al. Reliability of bladder volume measurement with BladderScan in paediatric patients. Scand J Urol Nephrol 2006; 40: 370-375.
11. Lankford SP, Peters KL, Elser RC. Potential effects of age-specific reference ranges for serum prostate-specific antigen. Eur Urol 1995; 27: 182-186.
12. Roehrborn CG. The epidemiology of acute urinary retention in benign prostatic hyperplasia. Rev Urol 2001; 3: 187-192.
13. Black L, Naslund MJ, Gilbert TD Jr, Davis EA, Ollendorf DA. An examination of treatment patterns and costs of care among patients with benign prostatic hyperplasia. Am J Manag Care 2006; 12(4 Suppl): 99-110.
14. McConnell JD, Bruskewitz R, Walsh P, Andriole G, Lieber M, Holtgrewe HL, et al. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride long-term efficacy and safety study group. N Engl J Med 1998; 338: 557-563.
15. McConnell JD, Roehrborn CG, Bautista OM, Andriole GL Jr, Dixon CM, Kusek JW, et al. The long-term effect of doxazosin, finasteride and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 2003; 349: 2387-2398.
16. Caine M, Pfau A, Perlberg S. The use of alpha-adrenergic blockers in benign prostatic obstruction. Br J Urol 1976; 48: 255-263.
17. Lepor H. Pathophysiology of lower urinary tract symptoms in the aging male population. Rev Urol 2005; 7 Suppl 7: s3-s11.
18. Chapple C. The contemporary pharmacological management of overactive bladder. BJOG 2006; 113 Suppl 2: s19-s28.
19. Athanasopoulos A, Gyftopoulos K, Giannitsas K, Fisfis J, Perimenis P, Barbalias G. Combination treatment with an α-blocker plus an anticholinergic for bladder outlet obstruction: a prospective, randomized, controlled study. J Urol 2003; 169: 2253-2256.
20. Lee N, Kim HW, Lee SJ, Koh JS, Suh HJ, Chancellor MB. Comparison of doxazosin with or without tolterodine in men with symptomatic bladder outlet obstruction and an overactive bladder. BJU Int 2004; 94: 817-820.
21. Kaplan SA. AUA guidelines and their impact on the management of BPH: an update. Rev Urol 2004; 6 Suppl 9: s46-s52.